Clinical trials: Endurance
Pulmonary Disease, Chronic Obstructive
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
The objective of this study is to demonstrate that, when added to tiotropium (TIO), fluticasone propionate/salmeterol combination (FSC) DISKUS 250/50 significantly increases exercise endurance time (EET) in the endurance shuttle…
- Trial name
- ESWT (NCT01124422)
- Testing
- fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler
- Where
- 27 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
This is a phase 2, Multi-center, double-blind, randomized, placebo-controlled study to evaluate the effects of inhaled Iloprost in patients with pulmonary hypertension secondary to COPD.
- Trial name
- NCT01437878
- Testing
- Iloprost
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 2 people
- Sponsor
- Actelion
Chronic Heart Failure
A Clinical Trial to Evaluate the HeartWare™ Ventricular Assist System (ENDURANCE SUPPLEMENTAL TRIAL)
This is a prospective, randomized, controlled, unblinded, multi-center evaluation of safety and efficacy in patients implanted with a HeartWare® HVAD who receive improved blood pressure management.
- Trial name
- DT2 (NCT01966458)
- Testing
- HeartWare® VAS (HVAD), Control LVAD
- Where
- 47 sites in United States
- Volunteers
- 494 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Pulmonary Disease, Chronic Obstructive
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444.
- Trial name
- COPD (NCT01323660)
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 307 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
This study compared the effect of indacaterol (300 μg once daily [od]) on exercise endurance with that of placebo in patients with moderate to severe chronic obstructive pulmonary disease.
- Trial name
- NCT00620022
- Testing
- Indacaterol 300 μg
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 90 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD
The primary objective of this study is to demonstrate that treatment with a free combination of tiotropium and salmeterol provides superior improvement in static lung volumes and exercise tolerance compared to a fixed combination…
- Trial name
- NCT00530842
- Testing
- Tiotropium plus Salmeterol, Fluticasone/Salmeterol
- Where
- 42 sites in Austria, Canada and 5 more
- Volunteers
- 344 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I
To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01040130
- Testing
- Olodaterol (BI 1744)
- Where
- 19 sites in Australia, Austria and 3 more
- Volunteers
- 151 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
The primary objective of this trial is to investigate the effect of 6 weeks treatment with tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and exercise tolerance in patients with COPD
- Trial name
- NCT01533922
- Testing
- Tiotropium, Olodaterol, tiotropium + olodaterol
- Where
- 44 sites in United States, Argentina and 8 more
- Volunteers
- 295 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
The main objectives of this study are: Determine the difference in change from baseline in Six Minute Walk Distance (6MWD) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with…
- Trial name
- NCT03717012
- Testing
- Nintedanib, Pulmonary rehabilitation program
- Where
- 19 sites in United States
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
COPD
Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the effect of once-daily indacaterol and glycopyrronium bromide (QVA149) on exercise endurance in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- BRIGHT (NCT01294787)
- Testing
- indacaterol and glycopyrronium bromide (QVA149), tiotropium
- Where
- 13 sites in Germany, Spain
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive, Exercise
Tiotropium In Exercise
The objective of this study is to evaluate the effects on exercise duration of 96 weeks treatment with 18 mcg tiotropium (Spiriva HandiHaler) daily as compared to placebo, in patients with COPD.
- Trial name
- NCT00525512
- Testing
- tiotropium 18 mcg
- Where
- 62 sites in United States, Argentina and 9 more
- Volunteers
- 519 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II
To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT01040793
- Testing
- Olodaterol (BI 1744), Olodaterol (BI1744)
- Where
- 19 sites in Austria, Belgium and 3 more
- Volunteers
- 157 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD.
- Trial name
- NCT00500318
- Testing
- Aclidinium Bromide
- Where
- 52 sites in United States, Canada
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444.
- Trial name
- COPD (NCT01328444)
- Testing
- GSK 573719 +GW642444 125/25, GSK573719 + GW642444 62.5/25, GSK 573719 125
- Where
- 31 sites in United States, Bulgaria and 4 more
- Volunteers
- 349 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, placebo-controlled, 2-period, complete block design cross-over study. The purpose of this study is to evaluate the effect of UMEC/VI 62.5/25 microgram (mcg) on EET as measured by…
- Trial name
- NCT02275052
- Testing
- UMEC/VI DPI, Albuterol/salbutamol MDI
- Where
- 10 sites in United States
- Volunteers
- 198 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
The primary objective of this study is to compare the effects of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 µg; 5/5 µg) with placebo on exercise tolerance after 12 weeks of treatment in patients with…
- Trial name
- NCT01525615
- Testing
- Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose)
- Where
- 60 sites in United States, Argentina and 8 more
- Volunteers
- 404 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The ability for patients with COPD to exercise is limited due to the deterioration of their lung function. NVA237 is being developed to treat COPD.
- Trial name
- GLOW3 (NCT01154127)
- Testing
- NVA237
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 108 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
The primary objective of this trial is to investigate the effect of 6 weeks treatment with tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and exercise tolerance in patients with COPD.
- Trial name
- NCT01533935
- Testing
- Tiotropium + Olodaterol, Tiotropium, Olodaterol
- Where
- 33 sites in United States, Argentina and 6 more
- Volunteers
- 291 people
- Sponsor
- Boehringer Ingelheim
Chronic Heart Failure
The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE Trial
The purpose of this study is to determine the safety and effectiveness of the HeartWare Ventricular Assist System in patients with chronic Stage D/ New York Heart Association (NYHA) Class IIIB/IV left ventricular failure who have…
- Trial name
- ENDURANCE (NCT01166347)
- Testing
- HeartWare® VAS, Control LVAD
- Where
- 48 sites in United States
- Volunteers
- 451 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The aim of the present study is to evaluate the effect of aclidinium bromide 400 μg twice a day (BID) administered twice a day versus placebo on exercise endurance and on hyperinflation and dyspnoea at rest and during exercise…
- Trial name
- NCT01471171
- Testing
- Aclidinium Bromide
- Where
- 14 sites in Germany, Spain and 1 more
- Volunteers
- 112 people
- Sponsor
- AstraZeneca